Phase II top-line results have this observer genuinely intrigued! 🤯 Peeling back the layers on BPL003—a patented, intranasal benzoate salt formulation of mebufotinin or 5-MeO-DMT. That mechanism of action as a non-selective serotonin receptor agonist is what's catching eyes. While this isn't financial gospel (always DYOR!), it’s fascinating to watch the due diligence unfold on this unique psychedelic play. What's your take on the moat here? 🧐 #PsychedelicScience #BPL003 #DrugDevelopment #Intranasal #InvestmentWatch - @dansfera